Patents by Inventor Mattias Ivarsson

Mattias Ivarsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION
    Publication number: 20230338401
    Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 26, 2023
    Applicants: ETH Zurich, Universitat Bern
    Inventors: Anna Kletzmayr, Makoto Kuro-o, Hirosaka Hayashi, Mattias Ivarsson, Jean-Christophe Leroux
  • Inositol derivatives for use in pathological crystallization
    Patent number: 11028112
    Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: June 8, 2021
    Assignees: ETH ZURICH, UNIVERSITAT BERN
    Inventors: Mattias Ivarsson, Bastien Castagner, Jean-Christophe Leroux, Andreas Pasch
  • INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION
    Publication number: 20200247837
    Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.
    Type: Application
    Filed: April 20, 2020
    Publication date: August 6, 2020
    Applicants: ETH Zurich, UNIVERSITAT BERN
    Inventors: Mattias IVARSSON, Bastien CASTAGNER, Jean-Christophe LEROUX, Andreas PASCH
  • Inositol derivatives for use in pathological crystallization
    Patent number: 10624909
    Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: April 21, 2020
    Assignees: ETH ZURICH, UNIVERSITAT BERN
    Inventors: Mattias Ivarsson, Bastien Castagner, Jean-Christophe Leroux, Andreas Pasch
  • 4,6-di-(O-thiophosphate)-inositol-1,2,3,5-tetra-O-sulfate for infection
    Patent number: 10487097
    Abstract: The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: November 26, 2019
    Assignee: ETH ZURICH
    Inventors: Mattias Ivarsson, Jean-Christophe Leroux, Bastien Castagner
  • INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION
    Publication number: 20190175627
    Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 13, 2019
    Applicants: ETH Zurich, UNIVERSITAT BERN
    Inventors: Mattias IVARSSON, Bastien CASTAGNER, Jean-Christophe LEROUX, Andreas PASCH
  • 4,6-DI-(O-THIOPHOSPHATE)-INOSITOL-1,2,3,5-TETRA-O-SULFATE FOR C. DIFFICILE INFECTION
    Publication number: 20180362554
    Abstract: The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.
    Type: Application
    Filed: December 12, 2016
    Publication date: December 20, 2018
    Applicant: ETH Zurich
    Inventors: Mattias IVARSSON, Jean-Christophe LEROUX, Bastien CASTAGNER
  • Pharmaceutical compounds for use in the therapy of clostridium difficile infection
    Patent number: 9751903
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 5, 2017
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20160280727
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: ETH Zurich
    Inventors: Bastien CASTAGNER, Jean-Christophe LEROUX, Mattias IVARSSON, Gisbert SCHNEIDER, Anna PRATSINIS
  • Pharmaceutical compounds for use in the therapy of infection
    Patent number: 9358243
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 7, 2016
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20140235590
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Applicant: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis